pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

avelas-biosciences PRESS RELEASE ARCHIVE

Sep 26, 2018

Avelas Biosciences to Present at 2018 Cantor Global Healthcare Conference

Aug 2, 2018

Avelas Biosciences Initiates Period 2 of Phase 2 Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery

Jun 14, 2018

Avelas Biosciences to Present at JMP Securities Annual Life Sciences Conference

Mar 21, 2018

Avelas Biosciences to Present at Needham & Company 17th Annual Healthcare Conference

Jan 4, 2018

Avelas Biosciences Completes Period 1 Patient Enrollment in Phase 2 Study of AVB-620 in Women with Primary, Nonrecurrent Breast Cancer Undergoing Surgery

Jan 3, 2018

Avelas Biosciences Broadens Management Team with Key Executive Additions

Nov 21, 2017

Avelas Biosciences to Present at Piper Jaffray Healthcare Conference

Sep 26, 2017

Newly Published Data Supports Avelas Biosciences' Investigational Ratiometric Activatable Fluorescent Peptide AVB-620 in Intraoperative Tumor Detection

Sep 14, 2017

Avelas Biosciences' AVB-620 Shows Sensitive In Vivo Visualization of Breast Cancer in Journal Publication

Aug 3, 2017

Avelas Biosciences Doses First Patient in Phase 2 Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery

Jun 13, 2017

Avelas Biosciences to Participate in JMP Securities Life Sciences Conference

May 4, 2017

Avelas Biosciences Appoints Steven Chen as Chief Medical Officer

Mar 29, 2017

Avelas Biosciences to Present at Needham & Company 16th Annual Healthcare Conference

Mar 14, 2017

Avelas Biosciences Appoints Alexey Vinogradov, Ph.D., to Board of Directors

Mar 7, 2017

Avelas Biosciences to Present at 29th Annual Roth Conference

Sep 8, 2016

Avelas Biosciences Completes Patient Enrollment for AVB-620 Phase 1b Clinical Trial

Aug 18, 2016

Avelas Biosciences Completes $20 Million Series C Financing

May 9, 2016

Avelas Biosciences Announces Positive Interim Phase 1b Results and Advances to Dose Expansion Stage

Apr 6, 2016

Avelas Biosciences to Present at the Needham & Company 15th Annual Healthcare Conference

Mar 8, 2016

Avelas Biosciences to Present at 28th Annual Roth Conference

Nov 20, 2015

Representative Scott Peters Visits Avelas Biosciences

Apr 16, 2015

Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients

Sep 10, 2014

Avelas Biosciences Extends Series B Financing to $7.4 Million to Support Clinical Development of Real-Time Cancer Visualization Technology

Jan 9, 2014

Avelas Biosciences Closes $6.85 Million in Series B Financing to Advance Real-Time Cancer Visualization Technology to Clinical Proof-of-Concept

Dec 6, 2012

Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development

Google Analytics Alternative